免疫再挑战在非小细胞肺癌治疗中的研究
Research on Immune Rechallenge in the Treatment of Non-Small Cell Lung Cancer
皇甫睿 1苗春蕾 1侯坤 2朱贲贲 2平耀东 3武世奎4
作者信息
- 1. 内蒙古医科大学药学院,呼和浩特 010110;北京大学肿瘤医院内蒙古医院药剂科,呼和浩特 010050
- 2. 北京大学肿瘤医院内蒙古医院药剂科,呼和浩特 010050
- 3. 北京大学肿瘤医院内蒙古医院药剂科,呼和浩特 010050;北京大学肿瘤医院暨北京市肿瘤防治研究所药剂科,恶性肿瘤发病机制及转化研究教育部重点实验室,北京 100142
- 4. 内蒙古医科大学药学院,呼和浩特 010110
- 折叠
摘要
目的 总结免疫再挑战在非小细胞肺癌(non-small cell lung cancer,NSCLC)治疗方面的研究进展及获益人群,为临床实践中NSCLC的治疗提供参考.方法 以"非小细胞肺癌""免疫检查点抑制剂""再挑战"等为关键词,采用主题词和自由词相结合的方法,检索了PubMed、Cochrane Library、embase、中国知网等数据库自建库起至2024年2月1日的相关文献.结果 共检索到相关文献526篇,有效文献40余篇.其中关于NSCLC再挑战的系统性评价/Meta分析6篇,临床研究5篇,其余大多数为回顾性真实世界研究.结论 分析了NSCLC免疫再挑战治疗的有效性及可控的免疫相关不良反应(immune-related adverse events,irAEs),并初步认为程序性细胞死亡蛋白配体 1(programmed cell death ligand 1,PD-L1)高表达(TPS≥50％)、美国东部协作肿瘤组(Eastern Cooperative Oncology Group,ECOG)体能状况(performance status,PS)评分较好(PS≤1分)及初始免疫治疗时间较长的患者更有可能从免疫检查点抑制剂(immune checkpoint inhibitors,ICIs)再挑战中获益.
Abstract
OBJECTIVE To summarize the research progress and beneficiary population of immune re challenge in the treatment of non-small cell lung cancer(NSCLC),and provide reference for the treatment of NSCLC in clinical practice.METHODS Using key-words such as"non-small cell lung cancer","immune checkpoint inhibitor","rechallenge",etc.,a combination of topic words and free words was used to search relevant literature from PubMed、Cochrane Library、embase、self-built databases such as China National Knowledge Infrastructure until February 1,2024.RESULTS A total of 526 relevant literature were retrieved,with over 40 valid arti-cles.Among them,there are 6 systematic reviews/Meta analyses on NSCLC rechallenge,5 clinical studies,and most of the rest are retro-spective real-world studies.CONCLUSION The effectiveness and controllable irAEs of immune rechallenge therapy for NSCLC were analyzed,and it was preliminarily believed that patients with high programmed cell death ligand 1(PD-L1)expression(TPS ≥ 50％),good performance status(PS)score in the Eastern Cooperative Oncology Group(ECOG)in the United States(ECOG-PS＜1)and longer initial immunotherapy time were more likely to benefit from ICIs rechallenge.
关键词
非小细胞肺癌/免疫治疗/再挑战/疗效/安全性Key words
non-small cell lung cancer/immunotherapy/rechallenge/therapeutic effect/security引用本文复制引用
出版年
2024
NETL
NSTL
万方数据